Effect of increased blood flow rate on renal anemia and hepcidin concentration in hemodialysis patients

BMC Nephrol. 2021 Jun 15;22(1):221. doi: 10.1186/s12882-021-02426-7.

Abstract

Background: Increasing the blood flow rate (BFR) is a useful method for increasing Kt/V and the clearance for low molecular solutes. Hemodialysis patients are often anemic due to hypoerythropoiesis and their chronic inflammatory state. Hepcidin, a hormone that regulates iron homeostasis, is considered as an indicator of iron deficiency in patients with end-stage renal disease. This study aimed to investigate the effects of an increased BFR during hemodialysis on serum hepcidin levels and anemia.

Methods: Between April 2014 and March 2016, 22 chronic dialysis patients (11 men [50.0 %]; mean [± standard deviation] age, 72 ± 12 years) undergoing maintenance hemodialysis treatment, thrice weekly, were enrolled and followed prospectively for 24 months. In April 2014, the BFR was 200 mL/min; in April 2015 this was increased to 400 mL/min, which was within acceptable limits. The dialysate flow rate remained stable at; 500mlL/min. Blood samples were collected in March 2015 and 2016. The primary endpoint was the comparison of the amounts of erythropoiesis-stimulating agent (ESA) required.

Results: The increased BFR increased the Kt/V and contributed to significantly decreased urea nitrogen (UN) (p = 0.015) and creatinine (Cr) (p = 0.005) levels. The dialysis efficiency was improved by increasing the BFR. Ferritin (p = 0.038), hepcidin (p = 0.041) and high-sensitivity interleukin-6 (p = 0.038) levels were also significantly reduced. The ESA administered was significantly reduced (p = 0.004) and the Erythropoietin Resistant Index (ERI) significantly improved (p = 0.031). The reduction rates in UN (p < 0.001), Cr (p < 0.001), and beta-2 microglobulin (p = 0.017) levels were significantly greater post the BFR increase compared to those prior to the BFR increase. However, hepcidin was not affected by the BFR change.

Conclusions: Increasing BFR was associated with hemodialysis efficiency, and led to reduce inflammatory cytokine interleukin-6, but did not contribute to reduce C-reactive protein. This reduced hepcidin levels, ESA dosage and ERI. Hepcidin levels were significantly correlated with ferritin levels, and it remains to be seen whether reducing hepcidin leads to improve ESA and iron availability during anemia management.

Keywords: Anemia; Blood flow rate; Erythropoietin; Hemodialysis; Hepcidin.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Blood Flow Velocity*
  • Blood Urea Nitrogen
  • C-Reactive Protein / metabolism
  • Creatinine / blood
  • Female
  • Ferritins / blood
  • Hepcidins / blood*
  • Humans
  • Interleukin-6 / blood
  • Iron Deficiencies / blood*
  • Iron Deficiencies / immunology
  • Kidney Failure, Chronic / blood
  • Kidney Failure, Chronic / therapy
  • Male
  • Middle Aged
  • Prospective Studies
  • Renal Dialysis*
  • beta 2-Microglobulin / blood

Substances

  • Hepcidins
  • IL6 protein, human
  • Interleukin-6
  • beta 2-Microglobulin
  • C-Reactive Protein
  • Ferritins
  • Creatinine